Citation Impact
Citing Papers
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
2008 Standout
PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex
2018 StandoutScienceNobel
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
2006 StandoutNobel
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
2010 Standout
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
2011
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease
2004
Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial
2004
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
2008
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
2002
Progression of nephropathy in type 2 diabetic patients
2004
Diabetic retinopathy
2010 Standout
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
2004 Standout
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
2006 Standout
Diabetic renal disease: from recent studies to improved clinical practice
2004
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
2003 Standout
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy
2005
The Failing Heart — An Engine Out of Fuel
2007 Standout
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
2008
Hypertension and diabetes
2002
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
2003 Standout
The metabolic syndrome
2010 Standout
Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents
2004
Evidence for renoprotection by blockade of the renin–angiotensin–aldosterone system in hypertension and diabetes
2006
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
2009 Standout
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
2005 Standout
Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes*
2003
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
2008
Vascular endothelial growth factor (VEGF) and VEGF-receptor expression in placenta of hyperglycemic pregnant women
2010
Management of High Blood Pressure in African Americans<subtitle>Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks</subtitle>
2003
Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
2005
The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007
2008
Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria
2002
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
2003 Standout
Chronic kidney disease
2011 Standout
A New Equation to Estimate Glomerular Filtration Rate
2009 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
2005
Diabetic Retinopathy
2012 Standout
The metabolic syndrome
2005 Standout
Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate
2012
Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney
2003
Graves' Ophthalmopathy
2010 Standout
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy
2004
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
2003 Standout
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
2003
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Nephropathy in Patients with Type 2 Diabetes
2002
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Chronic kidney disease: global dimension and perspectives
2013 Standout
Type 1 diabetes
2013 Standout
TGF-β and fibrosis in different organs — molecular pathway imprints
2009 Standout
Combination Therapy With an Angiotensin Receptor Blocker and an ACE Inhibitor in Proteinuric Renal Disease: A Systematic Review of the Efficacy and Safety Data
2006
Inflammation in atherosclerosis
2002 StandoutNature
Diabetes and advanced glycation endproducts
2002
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
2004
Age and Association of Kidney Measures With Mortality and End-stage Renal Disease
2012
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
2003
The RAAS in the pathogenesis and treatment of diabetic nephropathy
2010
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 Standout
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy
2004
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
2003
Population based screening for chronic kidney disease: cost effectiveness study
2010
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2004 Standout
Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study*
2005
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
2003 Standout
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
2006
The changing patterns of chronic kidney disease: The need to develop strategies for prevention relevant to different regions and countries
2005
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
2014
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
2002
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
2015 Standout
Chronic Kidney Disease
2016 Standout
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria
2005
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial
2002
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy
2003
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV
2004
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
Cell Biology of the Glomerular Podocyte
2003 Standout
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
2003 Standout
Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus
2002
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
2006
Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
2002
Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
2005 Standout
Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes
2005
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes
2003
Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update
2009
Protein Kinase C β Inhibition Attenuates the Progression of Experimental Diabetic Nephropathy in the Presence of Continued Hypertension
2003
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
2005 Standout
Diabetic Kidney Disease
2017 Standout
Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy
2002
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction
2004
Advanced glycation and retinal pathology during diabetes.
2005
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Kidney Disease and Cardiovascular Risk
2006
Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II–Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?
2009
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
2013 Standout
Diabetes and Vascular Disease
2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study
2003
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
2002
Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria
2003
Hematocrit, Independent of Chronic Kidney Disease, Predicts Adverse Cardiovascular Outcomes in Chinese Patients With Type 2 Diabetes
2006
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
2002 Standout
Works of M. E. Cooper being referenced
Anaemia in diabetes: is there a rationale to TREAT?
2006
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension
2001
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
2000
Cellular Mechanisms of Diabetic Vascular Hypertrophy
1999
The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
2000
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
2002
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.
1998